Jpmorgan Chase & CO Neoleukin Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$0.5 - $0.72 $36,372 - $52,375	-72,744 Reduced 99.69%	223 $0
Q4 2022 Feb 13, 2023	BUY	$0.4 - $0.55 $6,414 - $8,819	16,035 Added 28.17%	72,967 $37,000
Q3 2022 Nov 14, 2022	SELL	$0.69 - $1.33 $19,720 - $38,011	-28,580 Reduced 33.42%	56,932 $36,000
Q2 2022 Aug 11, 2022	BUY	$0.92 - $2.25 $53,292 - $130,335	57,927 Added 209.99%	85,512 $88,000
Q1 2022 May 11, 2022	SELL	$1.72 - $5.23 $253,913 - $772,073	-147,624 Reduced 84.26%	27,585 $52,000
Q4 2021 Feb 10, 2022	BUY	$4.65 - $7.75 $372,809 - $621,348	80,174 Added 84.36%	175,209 $845,000
Q3 2021 Nov 12, 2021	BUY	$6.05 - $9.66 $574,961 - $918,038	95,035 New	95,035 $688,000

199K

Ticker NLTX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 42,579,900
Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.